Sub-section menu :

Content :

Legislation: New US bill for tougher penalties for counterfeit medicines

Legislation: New US bill for tougher penalties for counterfeit medicines


Congress.gov and Securing Industry


A new bill (the Drug Diversion and Counterfeit Crackdown Act of 2017), introduced in May, looks to amend the Federal Food, Drug and Cosmetic Act, so that the penalties dished out to conmen counterfeiting medicines are on a par with criminals who divert legitimate drugs. This would aim at reducing the discrepancy currently existing between the two crimes, as a person guilty of producing and distributing counterfeit drugs in the US cannot be jailed for more than one year, nor fined more than USD 1,000, whereas diverting US-made drugs for foreign markets back into the US can lead to a 10-year prison sentence, and fines reaching USD 250,000.


H. R. 2376 - To amend the Federal Food, Drug, and Cosmetic Act to protect and strengthen the drug supply chain in the United States by closing several statutory gaps in the penalty provisions of such Act that apply to drug diversion and counterfeiting.

 

IRACM

ASOP EU

Fight the fakes